Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas

Glioblastomas develop de novo (primary glioblastomas) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). There is increasing evidence that these glioblastoma subtypes develop through different genetic pathways. Primary glioblastomas are characterized by EGFR and MDM2 amplification/overexpression, PTEN mutations, and p16 deletions, whereas secondary glioblastomas frequently contain p53 mutations. Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested. We carried out deletion mappings on chromosome 10, using PCR-based microsatellite analysis. LOH#10 was detected at similar frequencies in primary (8/17; 47%) and secondary glioblastomas (7/13; 54%). The majority (88%) of primary glioblastomas with LOH#10 showed LOH at all informative markers, suggesting loss of the entire chromosome 10. In contrast, secondary glioblastomas with LOH#10 showed partial or complete loss of chromosome 10q but no loss of 10p. These results are in accordance with the view that LOH on 10q is a major factor in the evolution of glioblastoma multiform as the common phenotypic end point of both genetic pathways, whereas LOH on 10p is largely restricted to the primary (de novo) glioblastoma.     

Genetic pathways to primary and secondary glioblastoma

Glioblastoma is the most frequent and most malignant human brain tumor. The prognosis remains very poor, with most patients dying within 1 year after diagnosis. Primary and secondary glioblastoma constitute distinct disease subtypes, affecting patients of different age and developing through different genetic pathways. The majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion. They affect mainly the elderly and are genetically characterized by loss of heterozygosity 10q (70% of cases), EGFR amplification (36%), p16(INK4a) deletion (31%), and PTEN mutations (25%). Secondary glioblastomas develop through progression from low-grade diffuse astrocytoma or anaplastic astrocytoma and manifest in younger patients. In the pathway to secondary glioblastoma, TP53 mutations are the most frequent and earliest detectable genetic alteration, already present in 60% of precursor low-grade astrocytomas. The mutation pattern is characterized by frequent G:C-->A:T mutations at CpG sites. During progression to glioblastoma, additional mutations accumulate, including loss of heterozygosity 10q25-qter ( approximately 70%), which is the most frequent genetic alteration in both primary and secondary glioblastomas. Primary and secondary glioblastomas also differ significantly in their pattern of promoter methylation and in expression profiles at RNA and protein levels. This has significant implications, particularly for the development of novel, targeted therapies, as discussed in this review.     

Genes implicated in glial tumors

Because of the absence of specific marker, the histological classification of gliomas remain controversial. Identifying the genetic alterations involved in gliomas makes it possible to define specific molecular pathway of tumoral progression and to define markers of prognostic and diagnostic relevance. For example, p53 mutations are frequent in low grade astrocytoma, anaplastic astrocytoma and secondary glioblastoma suggesting that it takes place at an early stage of development of astrocytic tumors, whereas inactivation of PTEN arises mainly in glioblastomas and EGFR amplification is preferentially associated with "de novo" glioblastoma. Loss of chromosomes 1p and 19q characterizes oligodendroglial tumors. However the putative tumor suppressor genes located on 1p and 19q and specifically inactivated are not known yet. Emerging technologies, like microarrays and microdissection, will allow to refine molecular data and provide a molecular classification of gliomas mechanism involved in the repair of the respiratory epithelium.     

Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas

Frequent allelic losses on the long arm of chromosome 22 (22q) in gliomas indicate the presence of tumor suppressor gene (TSG) at this location. However, the target gene(s) residing in this chromosome are still unknown and their putative roles in the development of astrocytic tumors, especially in secondary glioblastoma, have not yet been defined. To compile a precise physical map for the region of common deletions in astrocytic tumors, we performed a high-density loss of heterozygosity (LOH) analysis using 31 polymorphic microsatellite markers spanning 22q in a series of grade II diffuse astrocytomas, anaplastic astrocytomas, primary glioblastomas, and secondary glioblastomas that had evolved from lower grade astrocytomas. LOH was found at one or more loci in 33% (12/36) of grade II diffuse astrocytomas, in 40% (4/10) of anaplastic astrocytomas, in 41% (26/64) of primary glioblastomas, and in 82% (23/28) of secondary glioblastomas. Characterization of the 22q deletions in primary glioblastomas identified two sites of minimally deleted regions at 22q12.3-13.2 and 22q13.31. Interestingly, 22 of 23 secondary glioblastomas affected shared a deletion in the same small (957 kb) region of 22q12.3, a region in which the human tissue inhibitor of metalloproteinases-3 (TIMP-3) is located. Investigation of the promoter methylation and expression of this gene indicated that frequent hypermethylation correlated with loss of TIMP-3 expression in secondary glioblastoma. This epigenetic change was significantly correlated to poor survival in eight patients with grade II diffuse astrocytoma. Our results suggest that a 957 kb locus, located at 22q12.3, may contain the putative TSG, TIMP-3, that appears to be relevant to progression to secondary glioblastoma and subsequently to the prognosis of grade II diffuse astrocytoma. In addition, the possibility of other putative TSGs on 22q12.3-13.2 and 22q13.31 that may also be involved in the development of primary glioblastomas cannot be ruled out.     

Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma

The majority of glioblastomas develop rapidly with a short clinical history (primary glioblastoma IDH wild‐type), whereas secondary glioblastomas progress from diffuse astrocytoma or anaplastic astrocytoma. IDH mutations are the genetic hallmark of secondary glioblastomas. Gliosarcomas and giant cell glioblastomas are rare histological glioblastoma variants, which usually develop rapidly. We determined the genetic patterns of 36 gliosarcomas and 19 giant cell glioblastomas. IDH1 and IDH2 mutations were absent in all 36 gliosarcomas and in 18 of 19 giant cell glioblastomas analyzed, indicating that they are histological variants of primary glioblastoma. Furthermore, LOH 10q (88%) and TERT promoter mutations (83%) were frequent in gliosarcomas. Copy number profiling using the 450k methylome array in 5 gliosarcomas revealed CDKN2A homozygous deletion (3 cases), trisomy chromosome 7 (2 cases), and monosomy chromosome 10 (2 cases). Giant cell glioblastomas had LOH 10q in 50% and LOH 19q in 42% of cases. ATRX loss was detected immunohistochemically in 19% of giant cell glioblastomas, but absent in 17 gliosarcomas. These and previous results suggest that gliosarcomas are a variant of, and genetically similar to, primary glioblastomas, except for a lack of EGFR amplification, while giant cell glioblastoma occupies a hybrid position between primary and secondary glioblastomas.     

Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas

Glioblastoma multiforme, the most malignant human brain tumor, may develop de nova (primary glioblastoma) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastoma). We present further evidence that primary and secondary glioblastomas constitute distinct disease entities which develop through the acquisition of different genetic alterations. We analyzed p53 mutations, p53 protein accumulation and epidermal growth factor receptor (EGFR) overexpression in 49 biopsies classified as primary or secondary glioblastorna according to clinical and histopathologic criteria. Patients with primary glioblastoma were selected on the basis of a clinical history of less than 3 months and histopathologic features of glioblastoma at the first biopsy 119 cases; mean age, 55 years). The diagnosis of secondary glioblastomas required at least two biopsies and clinical as well as histologic evidence of progression from low grade or anaplastic astrocytoma (30 cases; mean age, 39 years). DNA sequence analysis showed that p53 mutations were rare in primary glioblastomas (11%) while secondary glioblastomas had a high incidence of p53 mutations (67%), of which 90% were already present in the first biopsy. The incidence of p53 protein accumulation (nuclear immunoreactivity to PAb 1801) was also lower in primary (37%) than in secondary glioblastornas (97%). In contrast, immunoreactivity for the EGF receptor prevailed in primary glioblastornas (63%) but was rare in secondary glioblastornas (10%). Only one out of 49 glioblastomas showed EGFR overexpression and a p53 mutation. These data indicate that overexpression of the EGF receptor and mutations of the p53 tumor suppressor gene are mutually exclusive events defining two different genetic pathways in the evolution of glioblastoma as the common phenotypic endpoint.     

原发性脑瘤的分子遗传学研究进展

［摘要］ 原发性脑瘤是发生于神经系统常见的疾病,高度恶性的胶质瘤占原发性脑瘤的40%,主要分为I型胶质母细胞瘤（继发性胶质母细胞瘤）和II型胶质母细胞瘤（原发性胶质母细胞瘤）,二者的产生有着不同的遗传学改变。I型胶质母细胞瘤的产生途径是从一种恶性程度较低的星形细胞瘤（II级,主要为p53基因突变和血小板来源的生长因子/受体过表达）至恶性的间变型星型细胞瘤（III级,主要为Rb基因突变,CDK4基因扩增,9p、11p、13q和19q的等位基因缺失）,再到胶质母细胞瘤（IV级,最常见的遗传学改变是7号和20号染色体的获得,10号染色体的丢失以及PTEN和LRRC4基因的缺失,PDGFα及其受体的过表达）的渐进的发展过程;而II型胶质母细胞瘤则是一种没有恶性程度渐进过程的原发性胶质母细胞瘤,表皮生长因子受体基因的扩增是最常见的遗传学改变。     

少突胶质细胞肿瘤染色体1p、19q和10q杂合性缺失与临床预后的关系

目的 探讨少突胶质细胞肿瘤微卫星变异的遗传和分子特性及其与临床预后的关系。方法 26例少突胶质细胞瘤和25例伴有少突胶质细胞瘤成分的胶质母细胞瘤成对的血和肿瘤标本DNA提取后,进行微卫星不稳定性分析染色体1、19q和10q杂合性缺失。结果 54％少突胶质细胞瘤检出1pLOH,58％检出19qLOH,35％检出10q LOH,其中50％间变性少突胶质细胞瘤出现10q LOH。1p／19q LOH相伴存,二者密切相关（P〈0．0001）;40％GBMO检出1pLOH,仅4例1p LOH伴10q LOH;60％检出19q LOH,64％检出10q LOH。结论 1P和19q LOH是少突胶质细胞瘤分子和遗传特性之一,并且与化疗敏感和预后好有关,10qLOH是少突胶质细胞瘤进展标志。1PLOH与长PFS有关,10qLOH与短PFS有关。GBMO分子表型不同于GBM。     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.     

少突胶质细胞瘤染色体1p/19 q杂合性缺失与p53蛋白表达的相关性研究

目的 探讨少突胶质细胞瘤染色体1p/19q杂合性缺失及p53蛋白的表达情况,与星形细胞起源的肿瘤进行比较研究并探讨其意义.方法 选择2004-2005年间,经病理组织学诊断为不同类型和级别的胶质瘤合计191例,包括:WHOⅡ级少突胶质细胞瘤116例,其中30例为新鲜组织;间变性少突胶质细胞瘤45例和不同级别星形细胞起源的肿瘤石蜡组织30例;采用PCR-微卫星技术检测染色体1p/19q杂合性缺失情况;采用免疫组织化学方法 对184例胶质瘤石蜡切片p53蛋白表达情况进行半定量分析.结果 86例WHO Ⅱ级少突胶质细胞瘤石蜡标本染色体1p缺失率为69.8%(60/86)、19q缺失率为64.0%(55/86)、1p/19q联合缺失率为57.0%(49/86);45例间变性少突胶质细胞瘤中,1p缺失率为71.1%(32/45)、19q缺失率为60.0%(27/45)、1p/19q联合缺失率为55.6%(25/45);两种级别间差异无统计学意义(P>0.05).30例WHO Ⅱ级少突胶质细胞瘤新鲜标本染色体1p缺失率为70.0%(21/30)、19q缺失率为63.3%(19/30)、1p/19q联合缺失率为60.0%(18/30),与石蜡标本的缺失率比较差异无统计学意义(P>0.05).30例星形细胞起源的肿瘤染色体对应三种缺失率分别为23.3%(7/30)、33.3%(10/30)及20.0%(6/30),与少突胶质细胞瘤差异有统计学意义(P<0.05).86例WHO Ⅱ级少突胶质细胞瘤中,仅7例有p53蛋白阳性表达(占8.1%);45例间变性少突胶质细胞瘤中,有14例呈阳性表达(31.1%),两者差异有统计学意义(P=0.007).少突胶质细胞瘤p53蛋白阳性表达明显低于星形细胞起源的肿瘤(P=0.001).在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关(P<0.05).结论 石蜡和新鲜组织均可用于染色体1p/19q杂合性缺失的检测.在间变性少突胶质细胞瘤中,染色体1p/19q杂合性缺失与p53蛋白阳性表达呈负相关.检测少突胶质细胞瘤染色体1p/19q杂合性缺失和p53蛋白表达,对提高病理诊断的精确性、指导治疗及预后判断具有重要意义.